8130. Foss, F.M., 2000. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clinical Lymphoma 1 (Suppl. 1), S27eS31. Gravalos, C., Jimeno, A., 2008. HER2 in gastric cancer: a brand new prognostic issue in addition to a novel therapeutic target. Annals of Oncology: Official Journal of your European Society for Health-related Oncology/ESMO 19 (9), 1523e1529. Honjo, T., Nishizuka, Y., Hayaishi, O., 1968. Diphtheria toxindependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis. The Journal of Biological Chemistry 243 (12), 3553e3555. Kintzer, A.F., et al., 2009. The protective antigen component of anthrax toxin types functional octameric complexes. Journal of Molecular Biology 392 (three), 614e629. Klimpel, K.R., et al., 1992. Anthrax toxin protective antigen is activated by a cell surface protease using the sequence specificity and catalytic properties of furin.5-Bromo-6-chloro-pyridine-2-carbaldehyde Formula Proceedings of the National Academy of Sciences with the United states of America 89 (21), 10277e10281. Koninki, K., et al., 2010. Many molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.Buy227454-58-2 Cancer Letters 294 (2), 211e219. Koo, H.-M., et al., 2002. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal issue inactivation of mitogen-activated protein kinase kinase. Proceedings of the National Academy of Sciences of the United states of America 99 (5), 3052e3057. Lacy, D.B., et al., 2004. Structure of heptameric protective antigen bound to an anthrax toxin receptor: a part for receptor in pHdependent pore formation. Proceedings in the National Academy of Sciences on the United states of America 101 (36), 13147e13151. Leppla, S.H., 1982. Anthrax toxin edema element: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proceedings on the National Academy of Sciences of your United states of america of America 79 (ten), 3162e3166. Lewis Phillips, G.D., et al., 2008. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Study 68 (22), 9280e9290. Liu, S., et al., 2000. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Study 60 (21), 6061e6067.M O L E C U L A R O N C O L O G Y 7 ( two 0 1 3 ) four four 0 e4 5Lofblom, J., et al., 2010. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Letters 584 (12), 2670e2680. Madhumathi, J., Verma, R.S., 2012. Therapeutic targets and current advances in protein immunotoxins. Existing Opinion in Microbiology.PMID:24487575 Mechaly, A., McCluskey, A.J., Collier, R.J., 2012. Altering the receptor specificity of anthrax toxin, pp. e00088e12. mBio three (3). Obtainable at: http://mbio.asm.org/content/3/3/ e00088-12. Miller, C.J., Elliott, J.L., Collier, R.J., 1999. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 38 (32), 10432e10441. Milne, J.C., et al., 1994. Anthrax protective antigen forms oligomers for the duration of intoxication of mammalian cells. The Journal of Biological Chemistry 269 (32), 20607e20612. Mogridge, J., et al., 2002. The lethal and edema elements of anthrax toxin bind only to oligomeric types in the protective antigen. Proceedings with the National Academy of Sciences on the Usa of America 99 (ten), 7045e7048. Nagy, P., et al., 2005. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer.